Covestor Ltd increased its position in Moderna, Inc. (NASDAQ:MRNA – Get Rating) by 230.3% in the 1st quarter, Holdings Channel.com reports. The firm owned 1,199 shares of the company’s stock after buying an additional 836 shares during the quarter. Covestor Ltd’s holdings in Moderna were worth $207,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Alerus Financial NA purchased a new position in shares of Moderna in the first quarter valued at $1,319,000. Parkside Financial Bank & Trust boosted its stake in shares of Moderna by 173.5% in the first quarter. Parkside Financial Bank & Trust now owns 309 shares of the company’s stock valued at $53,000 after purchasing an additional 196 shares during the period. Financial Advisors Network Inc. boosted its stake in shares of Moderna by 1,486.9% in the first quarter. Financial Advisors Network Inc. now owns 14,679 shares of the company’s stock valued at $2,529,000 after purchasing an additional 13,754 shares during the period. National Pension Service boosted its stake in Moderna by 8.0% during the 1st quarter. National Pension Service now owns 481,237 shares of the company’s stock valued at $82,898,000 after acquiring an additional 35,553 shares during the last quarter. Finally, Brighton Jones LLC boosted its stake in Moderna by 5.8% during the 1st quarter. Brighton Jones LLC now owns 1,856 shares of the company’s stock valued at $320,000 after acquiring an additional 102 shares during the last quarter. 60.76% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
MRNA has been the topic of a number of research analyst reports. SVB Leerink increased their price objective on shares of Moderna from $70.00 to $77.00 and gave the company an “underperform” rating in a research note on Monday, August 1st. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “hold” rating to a “buy” rating and increased their price objective for the company from $155.00 to $165.00 in a research note on Wednesday. Morgan Stanley reduced their price objective on shares of Moderna from $199.00 to $197.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 4th. Finally, Piper Sandler reduced their price objective on shares of Moderna from $348.00 to $214.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 17th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $227.75.
Moderna Stock Up 4.7 %
Moderna (NASDAQ:MRNA – Get Rating) last released its quarterly earnings data on Wednesday, August 3rd. The company reported $5.24 earnings per share for the quarter, topping analysts’ consensus estimates of $4.73 by $0.51. Moderna had a net margin of 61.12% and a return on equity of 94.76%. The business had revenue of $4.73 billion for the quarter, compared to analysts’ expectations of $3.95 billion. During the same quarter last year, the company earned $6.46 EPS. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. As a group, sell-side analysts predict that Moderna, Inc. will post 26.42 EPS for the current year.
Insider Buying and Selling
In related news, CEO Stephane Bancel sold 40,000 shares of the stock in a transaction dated Wednesday, June 22nd. The shares were sold at an average price of $136.58, for a total value of $5,463,200.00. Following the sale, the chief executive officer now owns 5,411,946 shares of the company’s stock, valued at approximately $739,163,584.68. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, Director Noubar Afeyan sold 10,000 shares of the stock in a transaction dated Wednesday, June 22nd. The shares were sold at an average price of $127.69, for a total value of $1,276,900.00. Following the completion of the transaction, the director now owns 2,527,209 shares in the company, valued at approximately $322,699,317.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Stephane Bancel sold 40,000 shares of the stock in a transaction dated Wednesday, June 22nd. The shares were sold at an average price of $136.58, for a total transaction of $5,463,200.00. Following the completion of the transaction, the chief executive officer now owns 5,411,946 shares of the company’s stock, valued at approximately $739,163,584.68. The disclosure for this sale can be found here. Insiders have sold a total of 557,570 shares of company stock valued at $89,311,945 in the last quarter. Company insiders own 17.30% of the company’s stock.
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.
- Get a free copy of the StockNews.com research report on Moderna (MRNA)
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- When Will the Hangover Finally Be Over for Seagate Technology?
- Are These Green Energy Companies Right For Your Portfolio?
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.